MLLT11 Antibody (2A9-1B7): sc-517101

MLLT11 Antibody (2A9-1B7) is a mouse monoclonal IgG2a kappa light chain antibody that detects the MLLT11 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-MLLT11 antibody (2A9-1B7) is available as a non-conjugated format. MLLT11, also known as mixed-lineage leukemia translocated to 11 or AF1q, is a 90 amino acid fusion partner of the Mixed-Lineage Leukemia (MLL) proteins, which are encoded by a gene located on chromosome 11q23. This region is critical as chromosomal translocations involving 11q23 are implicated in the development of rogue activator proteins associated with approximately 10% of acute lymphoblastic leukemia (ALL) cases and 5% of acute myeloid leukemia (AML) cases, predominantly affecting infants under one year of age. MLLT11 plays a significant role in leukemogenesis, particularly in the progression of acute monocytic leukemia, and is expressed in the embryonic brain cortex, where MLLT11 is upregulated during neuronal differentiation, indicating importance in central nervous system development. Additionally, MLLT11 exhibits differential expression in highly metastatic cells compared to their non-metastatic counterparts, suggesting involvement in tumorigenesis and highlighting potential as a target for therapeutic intervention in cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MLLT11 Antibody (2A9-1B7) References:

1. Analysis of MLL-derived transcripts in infant acute monocytic leukemia with a complex translocation (1;11;4)(q21;q23;p16).  |  So, CW., et al. 2000. Cancer Genet Cytogenet. 117: 24-7. PMID: 10700861
2. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.  |  Tse, W., et al. 2004. Blood. 104: 3058-63. PMID: 15217837
3. AF1q, a differentially expressed gene during neuronal differentiation, transforms HEK cells into neuron-like cells.  |  Lin, HJ., et al. 2004. Brain Res Mol Brain Res. 131: 126-30. PMID: 15530661
4. Increased AF1q gene expression in high-risk myelodysplastic syndrome.  |  Tse, W., et al. 2005. Br J Haematol. 128: 218-20. PMID: 15638856
5. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes.  |  Skotheim, RI., et al. 2006. Cell Oncol. 28: 315-26. PMID: 17167184
6. C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL.  |  Choi, WT., et al. 2007. Cancer Genet Cytogenet. 177: 108-14. PMID: 17854664
7. Identification of the functional role of AF1Q in the progression of breast cancer.  |  Chang, XZ., et al. 2008. Breast Cancer Res Treat. 111: 65-78. PMID: 17929166
8. MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.  |  Park, J., et al. 2016. Oncotarget. 7: 43960-43973. PMID: 27259262
9. MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.  |  Liao, J., et al. 2022. Cancer Biol Ther. 23: 211-224. PMID: 35253622
10. Mllt11 Regulates Migration and Neurite Outgrowth of Cortical Projection Neurons during Development.  |  Stanton-Turcotte, D., et al. 2022. J Neurosci. 42: 3931-3948. PMID: 35379703
11. MLLT11 siRNA Inhibits the Migration and Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells.  |  Liu, X., et al. 2023. Breast J. 2023: 6282654. PMID: 38075552
12. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells.  |  Tse, W., et al. 1995. Blood. 85: 650-6. PMID: 7833468